This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Invasive fungal infections in solid organ transplant recipients
Invasive fungal infections and chronic obstructive pulmonary disease
Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.
CRESEMBA® is an antifungal therapy for invasive aspergillosis, and mucormycosis where amphotericin B is inappropriate.1 Patients who are at risk of invasive aspergillosis or mucormycosis may include those with haematological malignancies, certain underlying conditions, undergoing HSCT, or being treated in the ICU.1–3
A 65-year-old male with AML currently on consolidation chemotherapy, with moderate renal dysfunction. Charles could be at risk of invasive aspergillosis or mucormycosis.
Download
A 70-year-old male with AML, currently on immunosuppressants and preparing for allogeneic HSCT. Mark could be at risk of invasive aspergillosis or mucormycosis.
Download
A 46-year-old female with influenza, currently on antiviral therapy and corticosteroids. Ruth could be at risk of invasive aspergillosis or mucormycosis.
Download
A 72-year-old female with ARDS, arterial hypertension and moderate renal impairment. Anika could be at risk of invasive aspergillosis or mucormycosis.
Download
A 76-year-old male with COVID-19, currently on corticosteroids. Sanjay could be at risk of invasive aspergillosis or mucormycosis.
CRESEMBA® is not indicated for the treatment of COVID-19
Download
A 66-year-old male with CLL, currently receiving ibrutinib treatment. Steve could be at risk of invasive aspergillosis or mucormycosis.
Download
AML, acute myeloid leukaemia; ARDS, acute respiratory distress syndrome; CLL, chronic lymphocytic leukaemia; COVID-19, coronavirus disease 2019; HSCT, haematopoietic stem cell transplantation.
Prescribing Information:
Click here for CRESEMBA® (isavuconazole) prescribing information
References:
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021